FrancophonIA/ELRC3.0 huggingface dataset:
English: The PRAC considered that these should be included in the product information and physicians advised to consider the patient's history before initiating treatment with SGLT2 inhibitors.
Estonian: Ravimiohutuse riskihindamiskomitee leidis, et need tuleb lisada ravimiteabesse ja soovitada arstidel kaaluda patsiendi anamneesi enne ravi alustamist SGLT2 inhibiitoritega.
English: No subset of the population at increased risk could be identified from the analysis of cases reported in clinical studies.
Estonian: Kliinilistes uuringutes teatatud juhtude analüüsist ei olnud võimalik tuvastada populatsiooni suurenenud riskiga alarühma.
English: When considering all the data submitted by the MAHs from clinical and non-clinical studies, postmarketing reports and in published literature, in relation to the risk of diabetic ketoacidosis (DKA) in association with SGLT2 inhibitors, the PRAC was of the view that a small excess risk could not be excluded in patients with T2DM.
Estonian: Kaaludes müügiloa hoidjate esitatud kõiki SGLT2 inhibiitoritega seotud diabeetilise ketoatsidoosi riski andmeid, mis pärinesid kliinilistest ja mittekliinilistest uuringutest, turustamisjärgsetest teadetest ja avaldatud kirjandusest, oli ravimiohutuse riskihindamiskomitee arvamusel, et T2DM-iga patsientidel ei saa välistada väikest riski suurenemist.
English: Further, restarting SGLT2 inhibitor medication in patients with previous DKA while on treatment is not recommended unless another clear precipitating factor is identified and resolved.
Estonian: SGLT2 inhibiitorravi taasalustamine varasema raviaegse diabeetilise ketoatsidoosiga patsientidel ei ole samuti soovitatav, välja arvatud juhtudel, kui on tuvastatud ja lahendatud selged soodustavad tegurid.
English: • The PRAC reviewed the totality of the data submitted by the marketing authorisation holders in relation to the risk of DKA in association with SGLT2 inhibitors-containing products and in support of the efficacy of SGLT2 inhibitors-containing products.
Estonian: • Ravimiohutuse riskihindamiskomitee vaatas üle kõik müügiloa hoidjate esitatud andmed diabeetilise ketoatsidoosi riski kohta seoses SGLT2 inhibiitoreid sisaldavate ravimitega ja nende efektiivsuse toetuseks.
English: DKA cases were reported in all three SGLT2 currently authorised in the EU, suggestive of a class effect.
Estonian: Diabeetilise ketoatsidoosi juhtudest teatati kõigi praegu ELis müügiluba omava kolme SGLT2 puhul, mis viitab ravimiklassile omasele toimele.
English: The PRAC, as a consequence, recommended the variation to the terms of the marketing authorisations for SGLT2 inhibitors-containing products.
Estonian: Seega soovitab ravimiohutuse riskihindamiskomitee muuta SGLT2 inhibiitoreid sisaldavate ravimite müügilubade tingimusi.
English: • The PRAC concluded that a small excess risk of DKA associated with SGLT2 inhibitors treatment in patients with T2DM could not be excluded.
Estonian: • Ravimiohutuse riskihindamiskomitee järeldas, et SGLT2 inhibiitorraviga seotud diabeetilise ketoatsidoosi veidi suurenenud riski T2DM-iga patsientidel ei saa välistada.
English: The relatively long time-to-onset observed in clinical trials is suggestive of contributing factors triggering the development of DKA.
Estonian: Kliinilistes uuringutes täheldatud suhteliselt pikk aeg kuni diabeetilise ketoatsidoosi alguseni viitab soodustavatele teguritele, mis vallandavad selle tekkimise.
English: In addition, the MAHs are required to clarify the mechanism behind SGLT2 inhibitors-induced DKA.
Estonian: Lisaks peavad müügiloa hoidjad välja selgitama SGLT2 inhibiitorite indutseeritud diabeetilise ketoatsidoosi tekkemehhanismi.
English: • The PRAC further concluded that a risk of DKA, including with atypical presentation, is also associated with the use of SGLT2 inhibitors in patients with T1DM.
Estonian: • Ravimiohutuse riskihindamiskomitee leidis samuti, et diabeetilise ketoatsidoosi, sealhulgas ebatüüpiliselt väljendunud diabeetilise ketoatsidoosi risk on samuti seotud SGLT2 inhibiitorite kasutamisega T1DM-iga patsientidel.
English: Considering the above, the PRAC was of the view that DKA should be included in the product information of all SGLT2 inhibitors with the frequency rare.
Estonian: Ravimiohutuse riskihindamiskomitee oli eeltoodut arvestades arvamusel, et kõigi SGLT2 inhibiitorite ravimiteabesse tuleb lisada diabeetiline ketoatsidoos sagedusega „harv”.
English: therefore the populations may not share the same baseline risk of DKA and careful consideration should be given to any direct incidence comparison.
Estonian: Veel kasutati ravimite kliinilistes arendusprogrammides erinevaid kaasamise ja mittekaasamise kriteeriume, mistõttu populatsioonidel ei pruugi olla samasugune esialgne diabeetilise ketoatsidoosi risk ning kõiki otseseid esinemissageduste võrdlusi tuleb hoolikalt kaaluda.
English: The PRAC further concluded that a risk of DKA, including with atypical presentation, is also associated with SGLT2 inhibitors treatment in patients with T1DM.
Estonian: Ravimiohutuse riskihindamiskomitee leidis samuti, et diabeetilise ketoatsidoosi, sealhulgas ebatüüpiliselt väljendunud diabeetilise ketoatsidoosi risk on samuti seotud SGLT2 inhibiitorraviga T1DM-iga patsientidel.
English: DKA typically occurs in T1DM patients with high blood glucose concentrations.
Estonian: Diabeetiline ketoatsidoos esineb tavaliselt suure veresuhkrukontsentratsiooniga T1DM-iga patsientidel.
English: In addition, a DUS, ideally based on secondary observational data via existing databases, is also required to be undertaken by the MAH of canagliflozin-containing products.
Estonian: Peale selle peab kanagliflosiini sisaldavate ravimite müügiloa hoidja korraldama ravimitarbimisuuringu, mis ideaalis põhineks teisestel jälgimisandmetel olemasolevatest andmebaasidest.
English: Importantly, DKA with atypical presentation may occur in association with SGLT2 inhibitors.
Estonian: Oluline on, et SGLT2 inhibiitoritega seoses võib esineda ebatüüpiliselt väljenduv diabeetiline ketoatsidoos.
English: Some of these effects were severe.
Estonian: Mõni kõrvalnäht oli raske.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Jevtana on 17 March 2011.
Estonian: Euroopa Komisjon andis Jevtana müügiloa, mis kehtib kogu Euroopa Liidus, 17. märtsil 2011.
English: What measures are being taken to ensure the safe and effective use of Jevtana?
Estonian: Mis meetmed võetakse, et tagada Jevtana ohutu ja efektiivne kasutamine?
English: The full EPAR for Jevtana can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Jevtana kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It must not be given to patients whose blood neutrophil count is below 1,500/mm3, who have severely reduced liver function or who recently received or are about to receive a yellow fever vaccine.
Estonian: Ravimit ei tohi kasutada patsiendid, kelle veres on neutrofiilide sisaldus alla 1500/mm3, kellel on raske maksapuudulikkus või kes on hiljuti saanud või peagi saavad kollapalaviku vaktsiini.
English: Other information about Jevtana
Estonian: Muu teave Jevtana kohta
English: It decided that Jevtana's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Komitee otsustas, et Jevtana kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: Jevtana cabazitaxel
Estonian: Jevtana kabasitakseel
English: What is Jevtana and what is it used for?
Estonian: Mis on Jevtana ja milleks seda kasutatakse?
English: With their skeleton still in place, the cells cannot divide and they eventually die.
Estonian: Kui raku sisetoes püsib, ei saa rakk jaguneda ning lõpuks hävib.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jevtana have been included in the summary of product characteristics and the package leaflet.
Estonian: Jevtana ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Why has Jevtana been approved?
Estonian: Miks Jevtana heaks kiideti?
English: What are the risks associated with Jevtana?
Estonian: Mis riskid Jevtanaga kaasnevad?
English: The most common side effects with Jevtana (seen in more than 1 patient in 10) include anaemia (low red blood cell counts), leucopenia (low white blood cell counts), neutropenia (low counts of neutrophils, a type of white blood cell), thrombocytopenia (low blood platelet counts) and diarrhoea.
Estonian: Jevtana kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on muu hulgas aneemia (erütrotsüütide ehk vere punaliblede vähesus), leukopeenia (leukotsüütide ehk vere valgeliblede vähesus), neutropeenia (neutrofiilide ehk vere teatud valgeliblede vähesus), trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus) ja kõhulahtisus.
English: Jevtana also affects non-cancer cells, such as blood and nerve cells, which can cause side effects.
Estonian: Jevtana mõjub ka muudele rakkudele peale vähirakkude, näiteks vere- ja närvirakkudele, mis võib põhjustada kõrvalnähte.
English: For more information about treatment with Jevtana, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Jevtanaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Both medicines were given in combination with prednisone or prednisolone.
Estonian: Kumbagi ravimit kasutati koos prednisooni või prednisolooniga.
English: This is a summary of the European public assessment report (EPAR) for Jevtana.
Estonian: See on ravimi Jevtana Euroopa avaliku hindamisaruande kokkuvõte.
English: It is given once every three weeks as an infusion lasting one hour, at a dose of 25 mg per square metre body surface area (calculated using the patient's weight and height).
Estonian: Jevtanat manustatakse üks kord kolme nädala järel ühetunnise infusiooniga annuses 25 mg kehapindala ruutmeetri kohta (arvutatakse patsiendi kehamassi ja pikkuse järgi).
English: Jevtana prolonged overall survival (the average length of time the patients lived) in one main study involving 755 men with metastatic castration-resistant prostate cancer who had previously been treated with docetaxel.
Estonian: Jevtana pikendas üldist elumust (keskmine aeg, kui kaua patsiendid elasid) ühes põhiuuringus, milles osales 755 kastreerimise suhtes resistentse metastaatilise eesnäärmevähiga meest, keda oli varem ravitud dotsetakseeliga.
English: Jevtana is used when the cancer has spread to other parts of the body (metastatic) despite treatments to prevent the production of testosterone or after surgical removal of the testes (castration).
Estonian: Jevtanat kasutatakse siis, kui vähk on levinud organismis ka mujale (metastaatiline) hoolimata testosterooni tootmist ennetavast ravist või pärast munandite kirurgilist eemaldamist (kastreerimine).
English: The doses should also be reduced in patients with mildly or moderately reduced liver function.
Estonian: Annust tuleb vähendada ka maksa kerge või mõõduka talitlushäirega patsientidel.
English: Jevtana is used in combination with prednisone or prednisolone (anti-inflammatory medicines) in patients who have previously been treated with docetaxel (another cancer medicine).
Estonian: Jevtanat kasutatakse koos prednisooni või prednisolooniga (põletikuvastased ravimid) patsientidel, keda on varem ravitud dotsetakseeliga (samuti vähiravim).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Jevtana.
Estonian: Selles selgitatakse, kuidas amet hindas ravimit, et soovitada müügiloa andmist Euroopa Liidus ja kasutustingimusi.
English: Before receiving Jevtana infusions, patients should first be given medicines to prevent allergic reactions and medicines to prevent vomiting.
Estonian: Patsientidele tuleb enne Jevtana infusiooni anda allergiariski ennetamiseks allergiaravimeid ja oksendamise ennetamise ravimeid.
English: For the full list of all side effects reported with Jevtana, see the package leaflet.
Estonian: Jevtana kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The average overall survival for patients treated with Jevtana was 15.1 months compared with 12.7 months for patients given mitoxantrone.
Estonian: Keskmine üldine elumus oli Jevtana uuringurühmas 15,1 kuud ja mitoksantrooni rühmas 12,7 kuud.
English: How does Jevtana work?
Estonian: Kuidas Jevtana toimib?
English: Jevtana must not be used in people who are hypersensitive (allergic) to cabazitaxel, to any other taxane, or to any of the other ingredients.
Estonian: Jevtanat ei tohi kasutada patsiendid, kes on kabasitakseeli, mõne muu taksaani või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: It is given in combination with prednisone or prednisolone, taken daily throughout treatment.
Estonian: Jevtanat kasutatakse koos prednisooni või prednisolooniga, mida võetakse üks kord ööpäevas kogu ravi ajal.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) considered that the ability of Jevtana to prolong overall survival in castration-resistant metastatic prostate cancer patients was clinically important.
Estonian: Inimravimite komitee otsustas, et Jevtana võime pikendada kastreerimise suhtes resistentse metastaatilise eesnäärmevähiga patsientide üldist elumust on kliiniliselt oluline.
English: Jevtana is a cancer medicine used to treat men with metastatic castration-resistant prostate cancer.
Estonian: Jevtana on vähiravim, mida kasutatakse kastreerimise suhtes resistentse metastaatilise eesnäärmevähiga meeste ravis.
English: How is Jevtana used?
Estonian: Kuidas Jevtanat kasutatakse?
English: The effects of Jevtana were compared with another cancer medicine, mitoxantrone.
Estonian: Jevtana toimet võrreldi teise vähiravimi mitoksantrooni toimega.
English: Jevtana contains the active substance cabazitaxel.
Estonian: Jevtana sisaldab toimeainena kabasitakseeli.
English: What benefits of Jevtana have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Jevtana kasulikkus?
English: Cabazitaxel works by blocking the ability of cancer cells to break down their internal ‘skeleton' that allows them to divide and multiply.
Estonian: Kabasitakseel blokeerib vähiraku võime lagundada enda sisetoest, et rakk saaks jaguneda ja paljuneda.
English: The dose of Jevtana should be reduced or treatment stopped if the patient has certain side effects.
Estonian: Teatud kõrvalnähtude esinemisel tuleb Jevtana annust vähendada või ravi katkestada.
English: This is cancer that affects the prostate gland in men that produces the liquid in semen.
Estonian: See vähk kahjustab eesnääret, mille eritis moodustab osa spermavedelikust.
English: Jevtana can only be obtained with a prescription and should only be used in units specialising in chemotherapy (medicines to treat cancer) under the supervision of a doctor experienced in the use of chemotherapy.
Estonian: Jevtana on retseptiravim ja ravi Jevtanaga peab toimuma keemiaravile (vähi ravimravi) spetsialiseerunud osakonnas keemiaravis kogenud arsti järelevalve all.
English: The active substance in Jevtana, cabazitaxel, belongs to the group of cancer medicines known as ‘taxanes'.
Estonian: Jevtana toimeaine kabasitakseel kuulub vähiravimite taksaanide rühma.
English: Jevtana is available as a concentrate and a solvent to be made up into a solution for infusion (drip) into a vein.
Estonian: Jevtanat turustatakse infusioonilahuse (veeni tilgutatav lahus) kontsentraadi ja lahustina.
English: * PD50- 50% protective dose in cattle as described in Ph. Eur.
Estonian: * PD50 - 50% kaitsev doos veistel, kirjeldatuna Ph. Eur.
English: A24 Cruzeiro and A Turkey 14/98 ≥ 6 PD50*
Estonian: A24 Cruzeiro ja A Turkey 14/98 ≥ 6 PD50*
English: O1 Manisa and O1 BFS ≥ 6 PD50*
Estonian: O1 Manisa ja O1 BFS ≥ 6 PD50*
English: A Turkey 14/98 and Asia 1 Shamir ≥ 6 PD50*
Estonian: A Turkey 14/98 ja Asia 1 Shamir ≥ 6 PD50*
English: A22 Iraq and A24 Cruzeiro ≥ 6 PD50*
Estonian: A22 Iraq ja A24 Cruzeiro ≥ 6 PD50*
English: A22 Iraq and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: A22 Iraq & SAT2 Saudi Arabia ≥ 6 PD50*
English: A22 Iraq, Asai1 Shamir and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: A22 Iraq, Asai1 Shamir & SAT2 Saudi Arabia ≥ 6 PD50*
English: A22 Iraq and Asia1 Shamir ≥ 6 PD50*
Estonian: A22 Iraq ja Asia1 Shamir ≥ 6 PD50*
English: A24 Cruzeiro, A Turkey 14/98 and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: A24 Cruzeiro, A Turkey 14/98 & SAT2 Saudi Arabia ≥ 6 PD50*
English: A24 Cruzeiro, Asia 1 Shamir and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: A24 Cruzeiro, Asia 1 Shamir & SAT2 Saudi Arabia ≥ 6 PD50*
English: A Turkey 14/98, Asia1 Shamir and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: A Turkey 14/98, Asia1 Shamir & SAT2 Saudi Arabia ≥ 6 PD50*
English: Asia1 Shamir and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: Asia1 Shamir & SAT2 Saudi Arabia ≥ 6 PD50*
English: A Turkey 14/98 and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: A Turkey 14/98 & SAT2 Saudi Arabia ≥ 6 PD50*
English: O Taiwan 3/97, A Turkey 14/98 and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O Taiwan 3/97, A Turkey 14/98 & SAT2 Saudi Arabia ≥ 6 PD50*
English: SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: Saudi Arabia ≥ 6 PD50*
English: A24 Cruzeiro and Asia 1 Shamir ≥ 6 PD50*
Estonian: A24 Cruzeiro ja Asia 1 Shamir ≥ 6 PD50*
English: A22 Iraq, A24 Cruzeiro and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: A22 Iraq, A24 Cruzeiro & SAT2 Saudi Arabia ≥ 6 PD50*
English: A24 Cruzeiro, A Turkey 14/98 and Asia1 Shamir ≥ 6 PD50*
Estonian: A24 Cruzeiro ja A Turkey 14/98 ja Asia1 Shamir ≥ 6 PD50*
English: A24 Cruzeiro and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: A24 Cruzeiro & SAT2 Saudi Arabia ≥ 6 PD50*
English: O Taiwan 3/97, Asia1 Shamir and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O Taiwan 3/97, Asia1 Shamir & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 Manisa, A Turkey 14/98 and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O1 Manisa, A Turkey 14/98 & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 Manisa and A22 Iraq ≥ 6 PD50*
Estonian: O1 Manisa ja A22 Iraq ≥ 6 PD50*
English: O1 Manisa, A24 Cruzeiro and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O1 Manisa, A24 Cruzeiro & SAT2 Saudi Arabia ≥ 6 PD50*
English: O Taiwan 3/97, A24 Cruzeiro and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O Taiwan 3/97, A24 Cruzeiro & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 Manisa, O Taiwan 3/97 and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O1 Manisa, O Taiwan 3/97 & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 Manisa and A24 Cruzeiro ≥ 6 PD50*
Estonian: O1 Manisa ja A24 Cruzeiro ≥ 6 PD50*
English: O1 BFS, O Taiwan 3/97 and A Turkey 14/98 ≥ 6 PD50*
Estonian: O1 BFS ja O Taiwan 3/97 ja A Turkey 14/98 ≥ 6 PD50*
English: O1 BFS, A22 Iraq and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O1 BFS, A22 Iraq & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 BFS, Asia1 Shamir and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O1 BFS, Asia1 Shamir & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 Manisa, Asia1 Shamir and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O1 Manisa, Asia1 Shamir & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 BFS, A24 Cruzeiro and A Turkey 14/98 ≥ 6 PD50*
Estonian: O1 BFS ja A24 Cruzeiro ja A Turkey 14/98 ≥ 6 PD50*
English: O1 Manisa, A24 Cruzeiro and A Turkey 14/98 ≥ 6 PD50*
Estonian: O1 Manisa ja A24 Cruzeiro ja A Turkey 14/98 ≥ 6 PD50*
English: O1 Manisa and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O1 Manisa & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 BFS, O Taiwan 3/97 and Asia1 Shamir ≥ 6 PD50*
Estonian: O1 BFS and O Taiwan 3/97 and Asia1 Shamir ≥ 6 PD50*
English: O1 BFS and A22 Iraq ≥ 6 PD50*
Estonian: O1 BFS ja A22 Iraq ≥ 6 PD50*
English: O1 BFS and A24 Cruzeiro ≥ 6 PD50*
Estonian: O1 BFS ja A24 Cruzeiro ≥ 6 PD50*
English: O Taiwan 3/97, A22 Iraq and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O Taiwan 3/97, A22 Iraq & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 BFS, O Taiwan 3/97 and A22 Iraq ≥ 6 PD50*
Estonian: O1 BFS ja O Taiwan 3/97 ja A22 Iraq ≥ 6 PD50*
English: O Taiwan 3/97 and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O Taiwan 3/97 & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 BFS and SAT2 Saudi Arabia ≥ 6 PD50*
Estonian: O1 BFS & SAT2 Saudi Arabia ≥ 6 PD50*
English: O1 Manisa, O Taiwan 3/97 and A22 Iraq ≥ 6 PD50*
Estonian: O1 Manisa ja O Taiwan 3/97 ja A22 Iraq ≥ 6 PD50*
English: O1 Manisa and Asia1 Shamir ≥ 6 PD50*
Estonian: O1 Manisa ja Asia1 Shamir ≥ 6 PD50*
English: O1 Manisa, O Taiwan 3/97 and A24 Cruzeiro ≥ 6 PD50*
Estonian: O1 Manisa ja O Taiwan 3/97 ja A24 Cruzeiro ≥ 6 PD50*
English: O Taiwan 3/97, A22 Iraq and A24 Cruzeiro ≥ 6 PD50*
Estonian: O Taiwan 3/97 ja A22 Iraq ja A24 Cruzeiro ≥ 6 PD50*
English: O1 BFS, A22 Iraq and Asia1 Shamir ≥ 6 PD50*
Estonian: O1 BFS ja A22 Iraq ja Asia1 Shamir ≥ 6 PD50*
English: O Taiwan 3/97, A24 Cruzeiro and Asia1 Shamir ≥ 6 PD50*
Estonian: O Taiwan 3/97 ja A24 Cruzeiro ja Asia1 Shamir ≥ 6 PD50*
English: O1 BFS, A Turkey 14/98 and Asia1 Shamir ≥ 6 PD50*
Estonian: O1 BFS ja A Turkey 14/98 ja Asia1 Shamir ≥ 6 PD50*
English: O1 BFS, A22 Iraq and A24 Cruzeiro ≥ 6 PD50*
Estonian: O1 BFS ja A22 Iraq ja A24 Cruzeiro ≥ 6 PD50*
English: O1 BFS and Asia1 Shamir ≥ 6 PD50*
Estonian: O1 BFS ja Asia1 Shamir ≥ 6 PD50*
English: O1 Manisa, A24 Cruzeiro and Asia1 Shamir ≥ 6 PD50*
Estonian: O1 Manisa ja A24 Cruzeiro ja Asia1 Shamir ≥ 6 PD50*
English: O1 Manisa, O Taiwan 3/97 and Asia1 Shamir ≥ 6 PD50*
Estonian: O1 Manisa jad O Taiwan 3/97 ja Asia1 Shamir ≥ 6 PD50*
English: O Taiwan 3/97, A Turkey 14/98 and Asia1 Shamir ≥ 6 PD50*
Estonian: O Taiwan 3/97 jad A Turkey 14/98 ja Asia1 Shamir ≥ 6 PD50*
English: O Taiwan 3/97 and A22 Iraq ≥ 6 PD50*
Estonian: O Taiwan 3/97 jad A22 Iraq ≥ 6 PD50*
English: O1 BFS, A24 Cruzeiro and Asia1 Shamir ≥ 6 PD50*
Estonian: O1 BFS ja A24 Cruzeiro ja Asia1 Shamir ≥ 6 PD50*
English: O Taiwan 3/97, A24 Cruzeiro and A Turkey
Estonian: O Taiwan 3/97 jad A Turkey
English: O Taiwan 3/97 and Asia1 Shamir ≥ 6 PD50*
Estonian: O Taiwan 3/97 jad Asia1 Shamir ≥ 6 PD50*
English: O1 Manisa, A Turkey 14/98 and Asia1 Shamir ≥ 6 PD50*
Estonian: O1 Manisa ja A Turkey 14/98 jad Asia1 Shamir ≥ 6 PD50*
English: A22 Iraq, A24 Cruzeiro and Asia1 Shamir ≥ 6 PD50*
Estonian: A22 Iraq ja A24 Cruzeiro jaAsia1 Shamir ≥ 6 PD50*
English: O1 BFS, O Taiwan 3/97 and A24 Cruzeiro ≥ 6 PD50*
Estonian: O1 BFS ja O Taiwan 3/97 jad A24 Cruzeiro ≥ 6 PD50*
English: O Taiwan 3/97, A22 Iraq and Asia1 Shamir ≥ 6 PD50*
Estonian: O Taiwan 3/97 ja A22 Iraq jaAsia1 Shamir ≥ 6 PD50*
English: O1 Manisa and A Turkey ≥ 6 PD50*
Estonian: O1 Manisa ja A Turkey 14/98 ≥ 6 PD50*
English: O1 BFS and O Taiwan ≥ 6 PD50*
Estonian: O1 BFS ja O Taiwan 3/97 ≥ 6 PD50*
English: O1 Manisa, O Taiwan 3/97 and A Turkey
Estonian: O1 BFS, O Taiwan 3/97 & SAT2
English: O1 BFS and A Turkey ≥ 6 PD50*
Estonian: O1 BFS ja A Turkey 14/98 ≥ 6 PD50*
English: O1 Manisa and O Taiwan ≥ 6 PD50*
Estonian: O1 Manisa ja O Taiwan 3/97 ≥ 6 PD50*
English: O Taiwan 3/97 and A Turkey 14/98 ≥ 6 PD50*
Estonian: O Taiwan 3/97 ja A24 Cruzeiro ja A Turkey 14/98 ≥ 6 PD50*
English: The results of these analyses are presented in the following tables.
Estonian: Nende analüüside tulemused on esitatud järgmises tabelis.
English: Efficacy in premature infants
Estonian: Efektiivsus enneaegsetel lastel
English: Justification for not including Braille accepted.
Estonian: Põhjendus Braille mitte lisamiseks aktsepteeritud.
English: Effectiveness % [95%CI]
Estonian: Efektiivsus % [95%CI]
English: In the general safety analyses, no specific safety concerns were identified.
Estonian: Üldises ohutusanalüüsis ei tuvastatud spetsiifilisi ohutusprobleeme.
English: There is limited evidence of a smaller increased risk following the second dose.
Estonian: Piiratult on tõendeid väiksema suurenenud riski kohta pärast teist annust.
English: A minor infection such as a cold should not be a problem, but talk to your doctor first.
Estonian: Väike nakkus, näiteks külmetus, ei tohiks olla probleemiks, kuid rääkige sellest esmalt arstile.